Brentuximab
Product Sizes
1 mg
£ POA
HY-P99151-1MG
5 mg
£ POA
HY-P99151-5MG
10 mg
£ POA
HY-P99151-10MG
100 mg
£ POA
HY-P99151-100MG
25 mg
£ POA
HY-P99151-25MG
50 mg
£ POA
HY-P99151-50MG
About this Product
- SKU:
- HY-P99151
- Additional Names:
- CAC-10
- Application:
- Antibody Microarray
- CAS Number:
- 2088770-90-3
- Extra Details:
- Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107). Brentuximab can inhibit tumor cell proliferation and prolong survival of mice. Brentuximab can be used for the research of cancer; such as lymphoma[1].
- Molecular Weight:
- (145.48 kDa)
- Purity:
- 99.64
- References:
- [1]Bhatt S, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug 15;122(7):1233-42. |[2]Chen R W, et al. Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model[J]. Blood, 2016, 128(22): 752.|[3]Wang Z, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13(7):1309-1319.
- Research Area:
- Cancer
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- Antibody-drug Conjugate/ADC Related;Apoptosis
